Amgen
Develops human therapeutics for various diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $14.4m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 2 % | 1 % | 7 % | 19 % | 7 % | 2 % | 3 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 36 % | 33 % | 53 % | 40 % | 50 % | 50 % | 49 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 23 % | 25 % | 24 % | 12 % | 17 % | 20 % | 22 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 19 % | 17 % | 17 % | 18 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Amgen is a leading biotechnology company focused on developing innovative medicines to serve patients and address serious illnesses. Operating in the healthcare and pharmaceutical markets, Amgen's core business involves the research, development, and commercialization of therapeutic solutions. The company primarily serves patients with serious diseases, healthcare providers, and medical institutions globally. Amgen's business model is centered around the discovery and development of biologic therapies, which are medicines derived from living organisms. These therapies are designed to treat conditions such as cancer, cardiovascular disease, and autoimmune disorders. The company generates revenue through the sale of its approved medicines and reinvests a significant portion of its earnings into research and development to discover new treatments. Amgen's commitment to innovation and patient care has positioned it as a key player in the biotechnology industry, with a strong pipeline of potential new therapies in various stages of development.
Keywords: biotechnology, innovative medicines, therapeutic solutions, serious illnesses, healthcare, pharmaceutical, biologic therapies, cancer, cardiovascular, autoimmune disorders.
Tech stack
